Actylis, a NYC-based provider of life sciences and advanced technology specialty ingredients, announced the strategic acquisition of Pharm-Rx, a Saddle Brook, NJ-based value-added supplier of specialty ingredients for the vitamin, mineral, and supplement (“VMS”) and pharmaceutical industries.
The amount of the deal was not disclosed.
The acquisition will improve Actylis’ ability to deliver value to its customers, increase its range of solutions for clients, and reinforce its strategic supplier partnerships to enhance its portfolio and service offerings. Pharm-Rx’s team and industry expertise broadens Actylis’ capabilities to help accelerate growth with nutrition and over-the-counter (OTC) pharmaceutical customers.
Pharm-Rx will continue to operate under its current brand within Actylis and be led by the current management team including Mark Bostel, Carlos Doussinague, and Ann Smith. Additionally, current President & Head of Business Development for Pharm-Rx, Mark Bostel, will be assuming the role of President, Global Nutrition and OTC for Actylis, leading both Pharm-Rx and Actylis’ Nutrition and OTC businesses.
Pharm-Rx is a supplier of nutritional, active pharmaceutical, and other specialty ingredients, collaborating with a worldwide network of suppliers to serve its customer base of contract manufacturers and branded companies. Its commitment is to build long-term business relationships through quality ingredients, competitive pricing, and exceptional customer service. The company connects vendors with its extensive network of leading brands and manufacturers, enhancing market presence and penetration. It focuses on offering innovative solutions from domestic and international markets including Asia, Africa, Europe, and South America for both nutritional and pharmaceutical products.
Led by CEO Scott Thomson, Actylis manufactures and supplies more than 3,000 chemical compounds used principally by the pharmaceutical, nutraceutical, agricultural, and specialty chemical industries. In the last four years, it has completed eight acquisitions, which have expanded its manufacturing, R&D, and portfolio offerings, becoming a worldwide supplier of critical ingredients with a robust manufacturing footprint. Its global operations, including a significant presence on the ground in China, India, Europe and North America, enable the company’s deep worldwide sourcing and regulatory capabilities.
Commenting on the news, Scott Thomson said: “We are thrilled to welcome Pharm-Rx into the Actylis family. This acquisition is a significant milestone in our growth strategy, allowing us to offer even greater value to our customers through an expanded portfolio and enhanced capabilities and expertise. By leveraging our combined strengths, we are poised to deliver the most innovative solutions to meet the ever-evolving needs of the markets that we serve. We are excited to welcome Mark Bostel to the Actylis leadership team and work together to drive accelerated growth for our combined nutrition and OTC business in partnership with our customers.”
FinSMEs
08/10/2024